VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. John Haanen on the Role of PD-L1 in Lung Cancer

John Haanen, MD, PhD
Published: Thursday, Apr 14, 2016



John Haanen, MD PhD, department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discusses the role of PD-L1 as a biomarker in lung cancer.

PD-L1 expression can be very dynamic, says Haanen. Therefore, PD-L1 expression may appear to be different depending on when the test was conducted.

PD-L1 expression of tumor cells or within the tumor microenvironment can be induced by the interaction between the immune system, T-cells, and the tumor. T-cells are activated when they recognize the tumor, a process which can sometimes induce PD-L1 expression, explains Haanen. This does not necessarily mean that PD-L1 is expressed all the time. Because PD-L1 is not always present in the tumor, it is not a reliable biomarker, says Haanen.

There does appear to be an association between outcomes and PD-L1 expression, especially with the PD-L1-directed agents; however it is not clear-cut, and therefor should not be used as a biomarker at this time in lung cancer, says Haanen.

<<< View more from the 2016 European Lung Cancer Conference



John Haanen, MD PhD, department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discusses the role of PD-L1 as a biomarker in lung cancer.

PD-L1 expression can be very dynamic, says Haanen. Therefore, PD-L1 expression may appear to be different depending on when the test was conducted.

PD-L1 expression of tumor cells or within the tumor microenvironment can be induced by the interaction between the immune system, T-cells, and the tumor. T-cells are activated when they recognize the tumor, a process which can sometimes induce PD-L1 expression, explains Haanen. This does not necessarily mean that PD-L1 is expressed all the time. Because PD-L1 is not always present in the tumor, it is not a reliable biomarker, says Haanen.

There does appear to be an association between outcomes and PD-L1 expression, especially with the PD-L1-directed agents; however it is not clear-cut, and therefor should not be used as a biomarker at this time in lung cancer, says Haanen.

<<< View more from the 2016 European Lung Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x